BMO Capital upgrades PayPal shares to Outperform from Market Perform, while reducing the price target to $224. Read More...
Motley Fool
Better Buy: Novavax vs. Moderna
Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) are two of the biotech industry’s biggest success stories from the coronavirus vaccine race. With Novavax’s jab racking up approval after approval in recent weeks, revenue will soon start to flood in, just as it did for Moderna. Is Moderna’s growth story approaching a plateau just as Novavax is starting its ascent with gusto, or will Moderna manage to increase its momentum?
Add Comment